Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024


First four CF patients demonstrated an average improvement of 4% FEV1 after two...

Related Keywords

United Kingdom ,China ,Japan ,California ,United States ,San Diego ,Scotland ,Joseph Payne ,Juergen Froehlich ,Linkedin ,Nasdaq ,Drug Administration ,Mrna Technology ,Arcturus Therapeutics Holdings Inc ,Twitter ,European Medicines Agency ,Arcturus Therapeutics Holdings ,European Cystic Fibrosis Conference ,Forced Expiratory Volume ,Chief Medical Officer ,Orphan Medicinal Product Designation ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Annual Report ,